Latest News & Features
Big Pharma
As the ‘UK+’ exhaustion regime is set to continue for now, Rebecca Anderson-Smith of Mewburn Ellis explores how pharma firms should protect their rights. 1 December 2022
article
Following the entering into force of Regulation 2017/746 of the European Parliament on in vitro diagnostic medical devices, an increasing number of medical products labelled “for research use only” rather than products bearing CE marking will be launched. Implications for patent litigation will be discussed based on relevant case law. 29 November 2022
Americas
Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University. 29 November 2022
Americas
German biopharma company’s complaint against Palo Alto competitor prompts commission to investigate | Patents in dispute relate to bio-layer interferometry. 28 November 2022
Americas
Conflict with name of patents for grapes and cherries prompts denial | If permitted, mark would “impede free use in the marketplace of a varietal denomination” following the patent’s expiration. 24 November 2022
Americas
Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic. 23 November 2022
Big Pharma
Large market for parallel or ‘grey’ imports of pharmaceuticals due to pricing differences in various countries | Govt consultation respondents unhappy with ‘lack of EU reciprocity’| Mewburn Ellis. 22 November 2022
Americas
Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million. 22 November 2022
Americas
Life sciences practice boosted by four-partner ‘powerhouse’ team | Attorneys have all achieved notable trial outcomes for pharma companies. 17 November 2022
Big Pharma
Judge Hacon rules that a skilled team “would have thought it obvious” to reformulate drug into a tablet | Teva DFX patents also found not to infringe, falling outside the claims on both a normal construction and under the doctrine of equivalents. 17 November 2022